Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled.

ABSTRACT:

Introduction

Immune system evasion is essential for tumor cell survival and is mediated by the immunosuppressive tumor microenvironment and the activation of inhibitory immune checkpoints. While immune checkpoint-based therapy yielded impressive results in several advanced solid malignancies such as melanoma and non-small cell lung cancer, its role in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) is still evolving. Areas covered: Here we review the immunology in the tumor microenvironment in the bone marrow and discuss the current preclinical and clinical data for immune checkpoint-based therapy in myeloid neoplasms. Expert commentary: Clinical trials of immune checkpoint inhibitors (ICI) in AML and MDS are still in early stages and reported results so far have be

SUBMITTER: Bewersdorf JP 

PROVIDER: S-EPMC6527485 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature